Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Will mTOR inhibitors make it as cancer drugs?

Sawyers CL.

Cancer Cell. 2003 Nov;4(5):343-8. Review. No abstract available.

3.

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG.

N Engl J Med. 2003 Mar 27;348(13):1201-14.

4.
5.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators.

N Engl J Med. 2003 Mar 13;348(11):994-1004.

6.

Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.

Wu CJ, Neuberg D, Chillemi A, McLaughlin S, Hochberg EP, Galinsky I, DeAngelo D, Soiffer RJ, Alyea EP, Capdeville R, Stone RM, Ritz J.

Leuk Lymphoma. 2002 Dec;43(12):2281-9.

PMID:
12613514
7.

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM.

Blood. 2003 May 1;101(9):3597-605. Epub 2003 Jan 16.

8.

Studying the pathogenesis of BCR-ABL+ leukemia in mice.

Van Etten RA.

Oncogene. 2002 Dec 9;21(56):8643-51. Review.

9.

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.

Druker BJ.

Oncogene. 2002 Dec 9;21(56):8541-6. Review. No abstract available.

10.

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control.

Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN.

Mol Cell. 2002 Sep;10(3):457-68.

11.

The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin.

McMahon LP, Choi KM, Lin TA, Abraham RT, Lawrence JC Jr.

Mol Cell Biol. 2002 Nov;22(21):7428-38.

13.

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.

Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13571-6. Epub 2002 Sep 23.

14.
15.

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM.

N Engl J Med. 2002 Aug 15;347(7):481-7.

16.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H.

N Engl J Med. 2002 Aug 15;347(7):472-80.

17.

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.

Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K.

Cell. 2002 Jul 26;110(2):177-89.

PMID:
12150926
18.
19.

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

Hoover RR, Mahon FX, Melo JV, Daley GQ.

Blood. 2002 Aug 1;100(3):1068-71.

20.

Critical role for Gab2 in transformation by BCR/ABL.

Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K, Gesbert F, Iwasaki H, Li S, Van Etten RA, Gu H, Griffin JD, Neel BG.

Cancer Cell. 2002 Jun;1(5):479-92.

Supplemental Content

Support Center